Teva Pharmaceuticals today issued a voluntary recall of seven lots of amikacin sulfate injection vials due to the possible presence of glass particulate matter in the drug.
Amikacin sulfate is an intravenous drug used for the short-term treatment of a variety of bacterial infections. The presence of glass particulate in the drug could result in irritation, swelling and blood clots.
The recalled lots were distributed to wholesalers, retailers and pharmacies across the country. Teva issued an Urgent Drug Recall Letter to customers, urging them to stop use or distribution and quarantine the product immediately.
So far, Israel-based Teva has not received any reports of adverse events or complaints over the recall.
More articles on supply chain:
Express Scripps adds new drugs to its exclusion list
Teva must divest 79 generics to acquire Allergan's generic pharma for $40.5 billion
America's Essential Hospitals partners with Premier to improve supply chain management